Abstract
The present study was designed to evaluate the risk of permanent linear growth impairment in a selected group of 42 children with steroid-dependent nephrotic syndrome (SDNS) and 14 children with frequently relapsing nephrotic syndrome (FRNS). Longitudinal height measurements were available in all patients from the onset of the disease for a mean follow-up of 11.7±3.5 years. During the prepubertal period, patients lost 0.49±0.6 height SD score (HtSDS) (P<0.001). Twenty-three patients have reached their final height with an average loss of 0.92±0.8 HtSDS from the onset of their disease (P<0.001) and 0.68±0.7 from their target HtSDS (P<0.001). The pubertal growth spurt was mildly delayed in male but not female patients. Steroid therapy, calculated as the mean duration of prednisone (PDN) treatment or as the average cumulative PDN dose, was the only predictor of poor growth evolution. Partial catch-up growth occurred after PDN withdrawal. Children with early onset NS and adolescent patients, who were still receiving PDN after the age of 9 years in girls and 11 years in boys, were at higher risk for HtSDS loss. In conclusion, children with severe steroid-responsive NS are at risk of permanent growth retardation secondary to prolonged courses of steroid treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lam CN, Arneil GC (1968) Long-term dwarfing effects of corticosteroid treatment for childhood nephrosis. Arch Dis Child 43:589–594
Rees L, Greene SA, Adlard P, Jones J, Haycock GB, Rigden SP, Preece M, Chantler C (1988) Growth and endocrine function in steroid sensitive nephrotic syndrome. Arch Dis Child 63:484–490
Padilla R, Brem AS (1989) Linear growth of children with nephrotic syndrome: effect of alkylating agents. Pediatrics 84:495–499
Berns JS, Gaudio KM, Krassner LS, Anderson FP, Durante D, McDonald BM, Siegel NJ (1987) Steroid-responsive nephrotic syndrome of childhood: a long-term study of clinical course, histopathology, efficacy of cyclophosphamide therapy, and effects on growth. Am J Kidney Dis 9:108–114
Chesney RW, Mazess RB, Rose P, Jax DK (1978) Effect of prednisone on growth and bone mineral content in childhood glomerular disease. Am J Dis Child 132:768–772
Foote KD, Brocklebank JT, Meadow SR (1985) Height attainment in children with steroid-responsive nephrotic syndrome. Lancet 2:917–919
Elzouki AY, Jaiswal OP (1988) Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr (Phila) 27:387–392
Polito C, Oporto MR, Totino SF, La Manna A, Di Toro R (1986) Normal growth of nephrotic children during long-term alternate-day prednisone therapy. Acta Paediatr Scand 75:245–250
Saha MT, Laippala P, Lenko HL (1998) Normal growth of prepubertal nephrotic children during long-term treatment with repeated courses of prednisone. Acta Paediatr 87:545–548
Clark AG, Barratt TM (1999) Steroid-responsive nephrotic syndrome. In: Barrat TM, Avner ED, Harmon WE (eds) Pediatric nephrology, 4th edn. Lippincott Williams and Wilkins, Baltimore, pp 731–747
Tanner JM, Whitehouse RH (1976) Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51:170–179
Gasser T (1991) Analysing curves using kernel estimators. Pediatr Nephrol 5:447–450
Cacciari E, Milani S, Balsamo A, Dammacco F, De Luca F, Chiarelli F, Pasquino AM, Tonini G, Vanelli M (2002) Italian cross-sectional growth charts for height, weight and BMI (6–20 y). Eur J Clin Nutr 56:171–180
Haffner D, Schaefer F, Nissel R, Wuhl E, Tönshoff B, Mehls O (2000) Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med 343:923–930
Tanner JM (1986) Normal growth and techniques of growth assessment. Clin Endocrinol Metab 15:411–451
Friedman M, Strang LB (1966) Effect of long-term corticosteroids and corticotrophin on the growth of children. Lancet 2:569–572
Scharer K, Essigmann HC, Schaefer F (1999) Body growth of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 13:828–834
Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS (1985) Long-term outcome for children with minimal-change nephrotic syndrome. Lancet I:368–370
Koskimies O, Vilska J, Rapola J, Hallman N (1982) Long-term outcome of primary nephrotic syndrome. Arch Dis Child 57:544–548
Jabs K, Sullivan EK, Avner ED, Harmon WE (1996) Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 61:31–36
Broyer M, Guest G, Gagnadoux MF (1992) Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr 120:721–725
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Emma, F., Sesto, A. & Rizzoni, G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol 18, 783–788 (2003). https://doi.org/10.1007/s00467-003-1176-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-003-1176-3